Cell Therapy · us
Dual-target CAR-T for lymphoma: 77% of evaluable patients achieve complete response in pivotal ronde-cel trial
Of 44 evaluable patients, 34 achieved a complete response, offering a new signal for lymphoma that has relapsed after multiple treatments. But how long the responses last and whether the therapy outperforms existing CAR-T treatments require more complete follow-up and randomized comparisons.
For patients whose lymphoma has relapsed or remains difficult to control after multiple lines of treatment, tumor regression is only the first hurdle; whether remission lasts is the longer-term test. On November 4, Lyell Immunopharma announced that its dual-target CAR-T candidate rondecabtagene autoleucel (ronde-cel) produced a complete response in 77% of evaluable patients in the pivotal PiNACLE trial. Preliminary follow-up also showed that some responses could last a year, but this remains an ongoing single-arm study.
PiNACLE is studying third-line or later treatment for relapsed or refractory large B-cell lymphoma. As of June 18, 2026, 58 patients had received treatment, of whom 44 were evaluable for response at day 84: 40 had an overall treatment response and 34 achieved a complete response, corresponding to 91% and 77%, respectively. Both percentages use evaluable patients as the denominator and cannot be directly interpreted as efficacy rates for all 58 treated patients. A complete response also does not mean a cure.
Ronde-cel is made from a patient's own T cells and can recognize CD19 or CD20 on the surface of B cells, with either marker serving as a cue for attack. The company also enriches CD62L-positive cells during manufacturing, hoping to increase the population of T cells with more durable function. Dual targeting and the cell manufacturing process provide a biological rationale for improving efficacy, but the current data cannot establish that these designs deliver better clinical outcomes than existing therapies.
Response duration provides another clue. According to the company's clinical and financial results announcements on the same day, among patients who had achieved a complete response, the estimated proportions maintaining a complete response at six and twelve months were 92% and 75%, respectively. Neither the median duration of complete response nor median progression-free survival had been reached. Median follow-up for the latter was twelve months. “Not reached” means the data are not yet mature enough to estimate a median; it does not support a conclusion that the disease will not progress again.
Safety must be assessed across all treated patients. Among the 58 patients in PiNACLE, no grade 3 or higher cytokine release syndrome was observed, but grade 1 and grade 2 events occurred in 48% and 22% of patients, respectively. The incidence of grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS) was 9%. The absence of severe cytokine release syndrome is one signal from these data, but it does not mean the treatment carries no serious risks.
A second-line cohort in another phase 1/2 trial also showed a similar response signal: among 37 evaluable patients, the overall response rate was 95% and the complete response rate was 76%. RTTNews reporting on efficacy and severe toxicity data for both groups was consistent with the company's announcements, but neither cohort provided randomized controlled results. The phase 3 PiNACLE-H2H trial, which is enrolling patients, will directly compare ronde-cel with approved CD19-targeted CAR-T therapies, offering an opportunity to answer the question of relative benefit more clearly.
Lyell expects to present data from more patients and longer follow-up at the American Society of Hematology annual meeting in December. It also plans to complete PiNACLE enrollment by the end of 2026, release pivotal data in mid-2027, and submit a U.S. biologics license application in the second half of that year. An approximately $80 million private placement announced the same day is expected to support clinical development and the application process. These remain the company's plans for advancing the program; whether the current high response rates translate into stable, reproducible treatment outcomes still depends on the complete data to come.